Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
medicine
Trimethoprim-sulfamethoxazole-induced hyperkalemia in patients receiving inhibitors of the renin-angiotensin system: A population-based study
Archives of Internal Medicine, Volume 170, No. 12, Year 2010
Notification
URL copied to clipboard!
Description
Background: Trimethoprim therapy can cause hyperkalemia and is often coprescribed with angiotensinconverting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs). The objective of this study was to characterize the risk of hyperkalemia-associated hospitalization in elderly patients who were being treated with trimethoprim-sulfamethoxazole along with either an ACEI or an ARB. Methods: We conducted a population-based, nested case-control study of a cohort of elderly patients 66 years or older who were residents of Ontario, Canada, and who were receiving continuous therapy with either an ACEI or an ARB. Case patients were those with a hyperkalemia-associated hospitalization within 14 days of receiving a prescription for trimethoprim-sulfamethoxazole, amoxicillin, ciprofloxacin, norfloxacin, or nitrofurantoin. For each case, we identified up to 4 control patients from the same cohort matched for age, sex, and presence or absence of chronic renal disease and diabetes. Odds ratios were determined for the association between hyperkalemia-associated hospitalization and previous antibiotic use. Results: During the 14-year study period, we identified 4148 admissions involving hyperkalemia, 371 of which occurred within 14 days of antibiotic exposure. Compared with amoxicillin, the use of trimethoprim-sulfamethoxazole was associated with a nearly 7-fold increased risk of hyperkalemia-associated hospitalization (adjusted odds ratio, 6.7; 95% confidence interval, 4.5-10.0). No such risk was found with the use of comparator antibiotics. Conclusions: Among older patients treated with ACEIs or ARBs, the use of trimethoprim-sulfamethoxazole is associated with a major increase in the risk of hyperkalemia-associated hospitalization relative to other antibiotics. Alternate antibiotic therapy should be considered in these patients when clinically appropriate. ©2010 American Medical Association. All rights reserved.
Authors & Co-Authors
Antoniou, Tony A.
Canada, Toronto
University of Toronto
Canada, Toronto
Saint Michael's Hospital University of Toronto
Gomes, Tara
Canada, Toronto
University of Toronto
Canada, Toronto
Institute for Clinical Evaluative Sciences
Juurlink, David Nelson
Canada, Toronto
University of Toronto
Canada, Toronto
Institute for Clinical Evaluative Sciences
Canada, Toronto
Sunnybrook Health Sciences Centre
Loutfy, Mona
Canada, Toronto
University of Toronto
Canada, Toronto
Women's College Hospital
Glazier, Richard Henry
Canada, Toronto
University of Toronto
Canada, Toronto
Saint Michael's Hospital University of Toronto
Canada, Toronto
Institute for Clinical Evaluative Sciences
Mamdani, Muhammad M.
Canada, Toronto
University of Toronto
Canada, Toronto
Li ka Shing Knowledge Institute
Canada, Toronto
Institute for Clinical Evaluative Sciences
Saudi Arabia, Riyadh
King Saud University
Statistics
Citations: 112
Authors: 6
Affiliations: 7
Identifiers
Doi:
10.1001/archinternmed.2010.142
ISSN:
00039926
e-ISSN:
15383679
Research Areas
Noncommunicable Diseases
Study Design
Cross Sectional Study
Cohort Study
Case-Control Study